Lexicon Pharmaceuticals, Inc. (LXRX) has announced that the company has commenced Phase 2a clinical trial for their LX6171 drug, a prevalent oral drug candidate. This drug will treat cognitive impairment, often associated with disorders such as Alzheimer’s disease, schizophrenia, and vascular dementia. Detailed information about this clinical trial will be available shortly.

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human diseases. Lexicon has various clinical programs underway, for such areas as irritable bowel syndrome, cognitive disorders, and rheumatoid arthritis. Since Lexicon’s formation, the company has discovered more than 100 promising drug targets, and is currently working on developing preclinical programs in each area.

Phillip M. Brown, MD and Vice President of Lexicon, stated, “AAMI is an emerging area of clinical research and offers an expedient population for obtaining proof-of-concept with a drug candidate, like LX6171, that has a broad range of potential applications in the area of cognitive disorders. Following the strength of the Phase 1 data indicating LX6171 is generally well tolerated, we have adopted a two-stage strategy for Phase 2a in order to transition to our new oral suspension formulation and to assess for improvements in a variety of cognitive dimensions as we enter the elderly population.”

Let us hear your thoughts below: